Table 3 TNF-a, IFN-g, and sFasL in c-SF-25-PBL-sup and m-SF-25-PBL-sup derived from healthy controls without human T-cell leukemia virus type I infection and patients with adult T-cell leukemia/lymphoma.

From: Chimeric SF-25 monoclonal antibody as a targeted therapy for SLC3A2 in adult T-cell leukemia/lymphoma

PBLs

TNF-α (pg/mL)

IFN-γ (pg/mL)

sFasL (pg/mL)

m-SF-25 Mab

c-SF-25 Mab

m-SF-25 Mab

c-SF-25 Mab

m-SF-25 Mab

c-SF-25 Mab

Healthy subject No.1

33.9 ± 7.2

956.7 ± 49.2

78.3 ± 4.5

1133.3 ± 57.3

< 100

629.9 ± 13.8

Healthy subject No.2

20.9 ± 9.5

1120.3 ± 20.1

55.3 ± 3.9

991.1 ± 23.4

< 100

773.5 ± 20.5

  1. Data represent the mean ± SD of triplicate assays.
  2. ATL adult T-cell leukemia/lymphoma; HTLV-1 human T-cell leukemia virus type I.
Back to article page